Recombinant Human MIP-4 (CCL18)
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Description | MIP-4 is a CC chemokine that is expressed in lymph nodes, lungs, placenta and bone marrow. MIP-4's primary receptor is unknown. MIP-4 chemoattracts lymphocytes, and has been shown to exert activity on both CD4+ and CD8+ T cells. Recombinant human MIP-4 is a 7.8 kDa protein containing 68 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines. |
---|---|
BiologicalActivity | Assay #1: Determined by its ability to chemoattract human T lymphocytes using a concentration of 1.0-10.0 ng/ml. Assay #2: Determined by its ability to chemoattract human iDCs using a concentration of 1.0-10.0 ng/ml. |
Authenticity | Verified by N-terminal and Mass Spectrometry analyses (when applicable). |
Endotoxin | Endotoxin level is <0.1 ng/ µg of protein (<1EU/ µg). |
Protein Content | Verified by UV Spectroscopy and/or SDS-PAGE gel. |
Storage | -20°C |
Precautions | Recombinant Human MIP-4 (CCL18) is for research use only and not for use in diagnostic or therapeutic procedures. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.